When healthy lung tissue is damaged by radiation, up to 20% of patients develop debilitating breathing difficulties that can leave them tethered to oxygen tanks. Researchers at City of Hope have identified a previously unknown immune mechanism driving this injury, offering a pathway to protect patients during cancer treatment.
Blocking IFN-Beta Reduces Radiation-Induced Lung Inflammation
- The Immune Shift: Radiation alters rare lung immune cells called innate lymphoid cells (ILCs), turning protective ILC2 cells into inflammatory ILC1 cells.
- The Molecular Switch: This damaging transformation is driven by a signaling protein known as interferon-beta (IFN-beta).
- The Therapeutic Target: Laboratory experiments show that blocking this IFN-beta signaling pathway during radiation significantly reduces lung inflammation, injury, and permanent fibrosis.
Uncovering the Immune Cell Transformation in Lungs
To investigate the cellular roots of this complication, a research team led by Heather McGee, M.D., Ph.D., developed a mouse model of radiation-induced lung injury. The investigation revealed that radiation provokes a dramatic transformation in innate lymphoid cells.
Under normal physiological conditions, ILC2 cells help safeguard the lungs from damage. Radiation exposure, however, reprograms these protective sentinels into ILC1 cells, which actively promote tissue-damaging inflammation. Subsequent testing on human ILCs confirmed similar biological shifts, establishing clinical relevance beyond laboratory models.
Much like a player switching teams, radiation-induced IFN-beta can shift these immune cells from a protective role to one that promotes inflammation,
stated corresponding author Heather McGee, M.D., Ph.D., an assistant professor in the departments of radiation oncology and immuno-oncology at City of Hope.
Targeting the IFN-Beta Signaling Pathway
The research team identified the precise molecular driver behind the cellular switch. Radiation exposure increases levels of interferon-beta (IFN-beta), acting as the biological catalyst that forces protective ILC2 cells to adopt an inflammatory identity. By pinpointing this mechanism, investigators could test targeted interventions.
When researchers disrupted the IFN-beta signaling pathway during radiation administration in mice, the results were pronounced. The targeted intervention successfully curbed inflammation, limited lung injury, and decreased subsequent fibrosis—the permanent scarring that stiffens pulmonary architecture and compromises respiratory capacity.
| Cell Type / Protein | Normal Pulmonary Function | Effect of Radiation Exposure |
|---|---|---|
| ILC2 Cells | Protects lung tissue from damage | Reprogrammed into ILC1s |
| ILC1 Cells | Promotes inflammation that damages healthy lung tissue | Expanded via transformation of ILC2s |
| Interferon-beta (IFN-beta) | Signaling protein | Increased levels, acting as the transformation switch |
Our findings suggest that high levels of IFN-beta contribute to the development of lung damage during radiation and that blocking this signaling pathway could offer a potential treatment to reduce this debilitating side effect,
explained first author Jaeho Kim, M.D., Ph.D., a radiation oncology postdoctoral fellow at City of Hope.
Implications for Cancer Patients and Chronic Conditions
Translating these preclinical insights into human clinical trials could fundamentally alter radiation oncology protocols. Successfully mitigating pulmonary toxicity would remove a primary barrier to administering higher, more tumor-icidal radiation doses in thoracic cancers.
Protecting healthy tissue from radiation damage could expand therapeutic options for individuals managing concurrent chronic respiratory pathologies, such as chronic obstructive pulmonary disease (COPD). By safeguarding pulmonary reserve, oncologists could safely treat patients who were previously considered poor candidates for aggressive radiation regimens.
References
- City of Hope.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional regarding cancer therapies and potential side effects.
